somaxon pharmaceuticals
Investor Relations
About Us Product Canidates Therapuetic Areas Insomnia Market Investor Releations News Contact Us
Home > Investor Relations

Investor Relations

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology.

Latest News

Jun 13, 2008
Somaxon Pharmaceuticals Appoints Erle T. Mast and Thomas G. Wiggans to its Board of Directors (pdf)

Jun 12, 2008
Silenor Data Presented at the 22nd Annual Meeting of the Associated Professional Sleep Societies

(pdf)

Webcasts

 

Stock Quote


SOMX(Common Stock)
Last Trade $3.32
Change down 0.11
Exchange NASDAQ
Volume 8,400

07/18/08 4:11 PM ET
Minimum 20 Minute Delay.
Refresh Quote.

Annual Report 2007

Annual Report




Join Our Mailing List

Please join our mailing list if you wish to receive news regarding Somaxon and its products.